




## World leader in manufacturing iPSCs consistently and at scale

**Now is the time** for more human-relevant *in vitro* models, powered by axoCells™ human iPSC-derived cells. Our market research has found that **75% of respondents** are increasing **iPSC investment** and **87%** see iPSCs as a **major tool for biopharma** - but the number one reported priority is **consistency**. At Axol, we're powering robust disease models with consistent, human-relevant cells manufactured at scale. Why? To accelerate drug discovery to deliver better, safer therapies for patients worldwide.

### 1 Manufacturing performance

- Batch runs of up to **250 x 1 million** vials of live axoCells microglia
- **75** manufacturing events to date in 2023 and **118** in 2022
- **49** products manufactured in house
- 2023 manufacturing run QC success rate – **92%**
- **100%** patient donor consent and licensing
- **6** specialist cell matched media



### 2 Delivery excellence

- 2023 OTIF – **97%** (target >93.5%)
- Complaints rate **0.2%**
- **24/7** remote storage monitoring and offsite backup

### 3 Experience & technical expertise

- **16** years of experience
- **13** PhDs
- **>140** years of collective technical expertise in-house



### 4 Commercial reach

- Over **1387** customers worldwide
- Supplying to **57** countries
- Serving **17** of the top 20 pharma
- Supplying **OEM** and **MPS** platform integration customers

